# US 2006/0156425 A1 · GNG4 gene disruptions, compositions and methods related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0156425 A1
- Document ID: US20060156425A1
- Status: Published application
- Kind: A1
- Application number: 11/298,008
- Filed: 2005-12-09
- Published: 2006-07-13
- Earliest claimed: 2001-09-24
- Inventors: Keith Allen; Christopher Kirk
- Web page: https://patentgrep.com/patent/US20060156425A1

## CPC

- A01K 67/0276: Knock-out vertebrates
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- A01K 2267/0375: Animal model for cardiovascular diseases
- A01K 2267/0393: Animal model comprising a reporter system for screening tests
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a GNG4 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

## Claims

### Claim 1

A transgenic mouse whose genome comprises a disruption in the GNG4 gene, said disruption comprising replacement of nucleotides corresponding to bases 178 to 245 of SEQ ID NO:1 with a LacZ-Neo cassette.

### Claim 2 (depends on 1)

The transgenic mouse of claim 1, wherein the disruption is heterozygous.

### Claim 3 (depends on 1)

The transgenic mouse of claim 1, wherein the disruption is homozygous.

### Claim 4 (depends on 3)

The transgenic mouse of claim 3, wherein the transgenic mouse exhibits increased body fat percentage relative to wild-type control mice.

### Claim 5 (depends on 1)

A method of producing the transgenic mouse of claim 1, the method comprising:
(a) providing a mouse stem cell comprising a disruption in the GNG4 gene, said disruption comprising replacement of nucleotides corresponding to bases 178 to 245 with a LacZ-Neo cassette;
(b) introducing the stem cell into a blastocyst;
(c) introducing the blastocyst into a pseudopregnant mouse, wherein the resulting mouse gives birth to chimeric mice; and
(d) breeding the chimeric mice to produce the transgenic mouse.
